赛诺医疗(688108) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2025 reached ¥123,378,511.92, representing a year-on-year increase of 17.73%[3]. - The total profit for the period was ¥10,506,327.09, with a year-to-date total profit of ¥33,516,889.46, reflecting a significant increase of 300.41% compared to the previous year[3][8]. - Net profit attributable to shareholders for Q3 was ¥7,276,401.53, marking a year-on-year growth of 150.51%[3][8]. - Total operating revenue for the first three quarters of 2025 reached ¥363,854,525.58, an increase of 14.3% compared to ¥318,486,443.24 in the same period of 2024[17]. - Net profit for the first three quarters of 2025 was ¥20,719,725.46, a significant recovery from a net loss of ¥14,931,400.83 in the same period of 2024[18]. - The total comprehensive income for the first three quarters of 2025 was ¥20,953,883.99, a recovery from a loss of ¥16,488,648.07 in the same period of 2024[18]. Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥83,974,895.27, an increase of 68.89% compared to the previous year[3][8]. - Cash inflow from operating activities for the first three quarters of 2025 is 413,401,906.35 CNY, an increase of 8.3% from 379,785,264.54 CNY in the same period of 2024[19]. - Cash outflow for investing activities is 31,015,450.99 CNY, down 66.0% from 91,099,183.91 CNY in the previous year[20]. - Net cash flow from investing activities is -30,981,098.74 CNY, an improvement from -72,000,968.51 CNY in the same period last year[20]. - Cash inflow from financing activities totals 73,934,400.00 CNY, a decrease of 39.3% from 121,906,687.94 CNY in the previous year[20]. - Net cash flow from financing activities is 13,663,827.42 CNY, down 77.0% from 59,422,575.01 CNY year-over-year[20]. - The ending balance of cash and cash equivalents is 357,698,265.28 CNY, compared to 224,939,661.92 CNY at the end of the previous year, reflecting a 59.0% increase[20]. Assets and Liabilities - Total assets increased by 2.94% from the previous year-end, reaching ¥1,338,809,666.31[4]. - Total liabilities increased slightly to ¥406,995,292.36 from ¥402,216,111.69, showing a growth of 1.9%[15]. - Total equity attributable to shareholders rose to ¥900,750,469.58 from ¥866,885,685.69, marking an increase of 3.9%[15]. - Accounts receivable increased to RMB 13,633,071.77 from RMB 7,473,696.25, representing an increase of approximately 82.5%[12]. - Inventory stood at RMB 102,766,470.80, up from RMB 89,505,811.67, indicating an increase of about 14.7%[13]. - Short-term borrowings increased to RMB 91,472,917.17 from RMB 53,049,209.71, marking an increase of approximately 72.2%[13]. Research and Development - Research and development expenses totaled ¥51,600,668.69 for the quarter, a decrease of 13.60% year-on-year, and accounted for 41.82% of operating revenue[3]. - Research and development expenses were ¥92,757,264.16, down from ¥106,407,498.18, indicating a 13% reduction[17]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 29,360[10]. - Tianjin Weixin Sunshine Enterprise Management Consulting Co., Ltd. holds 71,859,417 shares, accounting for 17.27% of the total shares[10]. - The company has not reported any significant changes in the shareholding structure or any related party transactions among the top shareholders[11]. - The company has not received any declarations regarding other shareholders having related party relationships or concerted action agreements[11]. Other Information - The company plans to continue focusing on market expansion and new product development to drive future growth[3]. - The company has not adopted new accounting standards or interpretations for the year 2025[21]. - The report is unaudited and prepared by Sino Medical Science Technology Co., Ltd[19].